Novo Nordisk cuts its voting interest in Seattle biotech

Article Abstract:

Novo Nordisk AS has reduced its voting interests in Zymogenetics Inc., a biotech firm based in Seattle. Novo Nordisk reduced its share to under 50%.

Securities issued, listed, Biotechnology industry, Biotechnology industries, Securities, ZymoGenetics Inc.

---

Bayer Joins Millenium in Drug Discovery. U.S. Firm Could Be Paid as Much as $465 Million

Article Abstract:

Bayer AG has signed an agreement with Millenium Pharmaceuticals Inc. Bayer will provide funding to Millenium for its DNA research ability. Millenium will provide 225 biological targets for Bayer to further develope. Bayer must decide to develope or not to develope within a given time. If Bayer decides not to persue a target, Millenium can either develope it, or offer it to a third party. Also, Bayer can reconsider the decision and can pay a fee to develope the target. This agreement is unusual, as most agreements of this kind are limited to a specific disease. Bayer made this agreement to increase its presence in genetic mapping, and resulting drug discoveries.

Comment:

Bayer will pay Millenium Pharmaceuticals Inc. to provide genetic research material for possible drug development

Germany, Use of services, Capital expenditures, New orders received, Pharmaceutical Preparation Manufacturing, Pharmaceutical Preparations, Bayer AG, Millennium Pharmaceuticals Inc., Article

---

Novo Nordisk plans radical corporate strategy

Article Abstract:

Novo Nordisk AS revealed a important change in strategy that called into question the company's independence over the long-term. The Danish-based drug manufacturer conducted a strategic review that established plans for a major corporate overhaul. Novo Nordisk is proposing to divide its pharmaceutical and enzyme divisions into individual legal entities. In the past, the company believed that the divisions belonged together because of production synergies.

Comment:

Reveals important change in strategy that calls into question co's independence over the long-term

Strategy & planning, Denmark, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Planning, Abstract

Similar abstracts:

• Abstracts: Alterra warns of loss in 4th quarter and a charge of up to $43 million. Minnesota Mining's profit beats estimates amid demand in Asia
• Abstracts: Shell sees the benefits of its drastic overhaul; Oil company plans $6 billion share buyback. Oil and chemical giants plan Web procurement exchange
• Abstracts: Users Follow the Pop-Up Window And Discover a Higher Phone Bill. Faceless web gives fraudsters ideal set for credit-card crimes
• Abstracts: Experts Probing Theory Of Abrupt Climate Shift Discover a Rich Patron. Karstadt reports loss of Euro49.6 million in 1st half
• Abstracts: Russian tycoon rises from dead; investors feel ill; Mr. Smolensky is back, without their $1 billion. Russian Bank's assets were spirited away

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.